BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36347548)

  • 1. How can we best manage biochemical failure after radical prostatectomy?
    Kim WT; Kim J; Kim WJ
    Investig Clin Urol; 2022 Nov; 63(6):592-601. PubMed ID: 36347548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review.
    Artibani W; Porcaro AB; De Marco V; Cerruto MA; Siracusano S
    Urol Int; 2018; 100(3):251-262. PubMed ID: 29161715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to biochemical relapse after radical prostatectomy and efficacy of salvage radiotherapy in patients with prostate cancer.
    Pak S; You D; Jeong IG; Kim YS; Hong JH; Kim CS; Ahn H
    Int J Clin Oncol; 2019 Oct; 24(10):1238-1246. PubMed ID: 31087170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
    Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
    Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.
    Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
    Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage radiation therapy following radical prostatectomy. A national Danish study.
    Ervandian M; Høyer M; Petersen SE; Sengeløv L; Hansen S; Holmberg M; Sveistrup J; Meidahl Petersen P; Borre M
    Acta Oncol; 2016 May; 55(5):598-603. PubMed ID: 26399602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
    Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
    Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
    Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
    J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
    Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T;
    Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
    Song C; Kim YS; Hong JH; Kim CS; Ahn H
    BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial.
    Tremblay S; Alhogbani M; Weickhardt A; Davis ID; Scott AM; Hicks RJ; Metser U; Chua S; Davda R; Punwani S; Payne H; Tunariu N; Ho B; Young S; Singbo MNU; Bauman G; Emmett L; Pouliot F
    Cancer Imaging; 2023 Jun; 23(1):57. PubMed ID: 37291656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing biochemical recurrence in patients who have received salvage radiotherapy after radical prostatectomy: a systematic review and meta-analysis.
    Jia ZW; Chang K; Dai B; Kong YY; Wang Y; Qu YY; Zhu YP; Ye DW
    Asian J Androl; 2017; 19(4):493-499. PubMed ID: 27241314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
    BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
    Preisser F; Abrams-Pompe RS; Stelwagen PJ; Böhmer D; Zattoni F; Magli A; Rivas JG; Dilme RV; Sepulcri M; Eguibar A; Heidegger I; Arnold C; Fankhauser CD; Chun FK; van der Poel H; Gandaglia G; Wiegel T; van den Bergh RCN; Tilki D;
    Eur Urol; 2024 Feb; 85(2):164-170. PubMed ID: 37355358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study.
    Miyake M; Tanaka N; Asakawa I; Morizawa Y; Anai S; Torimoto K; Aoki K; Yoneda T; Hasegawa M; Konishi N; Fujimoto K
    Radiat Oncol; 2014 Oct; 9():208. PubMed ID: 25331298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.